N/A N=49 Vaginally Assisted Laparoscopic Hysteropexy Versus Vaginal Hysterectomy
Pelvic Organ Prolapse
Primary: Number of Participants With Recurrence of Pelvic Organ Prolapse — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=337 Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial
Pelvic Organ Prolapse
Primary: Number of Participants With Treatment Failure Defined as Subsequent Treatment for Urinary Incontinence, Signs or Symptoms of Bothersome Urinary Incontinence — 39; 85…
N/A N=374 Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial
Pelvic Organ Prolapse (POP)
Primary: Surgical Success — 25; 30; 28; 27 Participants
N/A N=48 A Long Term Follow up of Anterior Meshes for Recurrent Prolapse
Genital Diseases, Female · Pelvic Organ Prolapse
Primary: The Number of Participants With a Current Mesh Erosion or Treated for a Mesh Erosion Since Inserted — 5 Participants
N/A N=190 Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse.
Pelvic Organ Prolapse
Primary: Prolapse by "Pelvic Organ Prolapse Quantification System" (POP-Q), at 12 Months — 8; 38; 75; 46 participants — p=<0.05
N/A N=272 Smartmesh Technology in Pelvic Floor Repair Procedures
Pelvic Organ Prolapse
Primary: Number of Patients With a Composite Outcome : Bladder Wound, Rectum Wound, Abnormal Bleeding — 6 Participants
Phase 2 N=283 Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in the Severity of Vaginal Dryness — 15; 13; 13; 9 Participants — p==0.304
Phase 3 N=167 Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in Maturation Value (MV) After 12 Weeks of Treatment — 26.9; 3.2 vaginal health index — p=<0.001
N/A N=44 A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension
Pelvic Organ Prolapse · Cystocele · Uterine Prolapse
Primary: Pelvic Organ Prolapse Quantification Exam (POP-Q) Point C — -7.25; -7 cm
N/A N=35 Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue
Bacterial Vaginosis · Vaginal Discharge
Primary: p24 Antigen Production in Tissue
Phase 4 N=28 Examining the Impact of Tampon Use on the Vaginal Microbiota
Vaginal Microbiota
Primary: Change in Relative Abundance of Lactobacillus Species — .0084; -.0014; -.00004; .0104 relative abundance
N/A N=173 Comparing Force of Stream to Retrograde Fill Voiding Trial After Vaginal Apex Suspension
Vaginal Apical Prolapse
Primary: Number of Subjects Catheterized Within the Six-week Post-operative Period Following Surgical Repair of Prolapse, Among Those Discharged Without a Urinary Catheter. — 2…
Phase 4 N=199 Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen
Pelvic Organ Prolapse · Urogenital Prolapse · Vaginal Vault Prolapse
Primary: Surgical "Failure" Defined by (i) Anatomic Assessment of Prolapse, (ii) Presence of Bulge Symptoms, and/or (Iii) Retreatment of Prolapse — 18; 8 Participants
Phase 4 N=30 Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor
Pelvic Organ Prolapse · Menopause
Primary: Vaginal Wall Composition: Epithelium (Intention to Treat) — 413.9; 314.1 microns — p=0.21
N/A N=183 Study of Uterine Prolapse Procedures - Randomized Trial
Uterovaginal Prolapse
Primary: Cumulative Failure — 78; 69; 9; 16 Participants